# Immunogenicity and Safety Study of Serum-Free Avonex

> **NCT00912860** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 155 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Interferon beta-1a

## Key facts

- **NCT ID:** NCT00912860
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2004-12
- **Final completion:** 2005-01
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2009-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00912860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00912860, "Immunogenicity and Safety Study of Serum-Free Avonex". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00912860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*